Upgrade to SI Premium - Free Trial

Mizuho Securities Remains Neutral on Myriad Genetics (MYGN); Awaiting Reimbursement Progress

February 3, 2016 8:07 AM
Mizuho Securities reiterated a Neutral rating and $42.00 price target on Myriad Genetics (NASDAQ: MYGN) following the company's 2Q earnings ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst EPS View

Next Articles